Clinical and laboratory prognostic factors in patients with
metastatic renal cell carcinoma treated with sunitinib and
sorafenib after progression on cytokines

J 2014

Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines

POPRACH, A.; Tomáš PAVLÍK; B. MELICHAR; K. KUBACKOVA; Zbyněk BORTLÍČEK et. al.

Basic information

Original name

Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines

Authors

POPRACH, A. (203 Czech Republic); Tomáš PAVLÍK (203 Czech Republic, belonging to the institution); B. MELICHAR (203 Czech Republic); K. KUBACKOVA (203 Czech Republic); Zbyněk BORTLÍČEK (203 Czech Republic, belonging to the institution); M. SVOBODA (203 Czech Republic); R. LAKOMY (203 Czech Republic); R. VYZULA (203 Czech Republic); I. KISS (203 Czech Republic); Ladislav DUŠEK (203 Czech Republic, guarantor, belonging to the institution) and T. BUEHLER (203 Czech Republic)

Edition

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, New York, ELSEVIER SCIENCE INC. 2014, 1078-1439

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

is not subject to a state or trade secret

Impact factor

Impact factor: 2.768

RIV identification code

RIV/00216224:14110/14:00075662

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.urolonc.2013.09.011

UT WoS

000335422300017

EID Scopus

2-s2.0-84899493581

Keywords in English

renal cell carcinoma; prognosis; survival; sunitinib; sorafenib

Abstract

V originále

Objectives: The aim of this retrospective study was to analyze prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors (TKIs) sunitinib or sorafenib after progression on cytokine therapy. Materials and methods: A national database of patients treated with targeted agents was used as the data source. A total of 319 patients treated with sunitinib (n = 181) or sorafenib (n = 138) after progression on cytokine therapy were analyzed. Results: Prognostic factors significantly associated with poor overall survival in a multivariable Cox model included the time from diagnosis to the start of treatment with TKIs <1 year, increased neutrophil counts, increased lactate dehydrogenase, and Eastern Oncology Cooperative Group performance status 2 or higher. The parameters showing statistically significant association with progression-free survival included time from diagnosis to the beginning of treatment with TKI <1 year, increased lactate dehydrogenase, and Eastern Oncology Cooperative Group performance status 2 or higher. We have also validated the International Metastatic Renal Cell Carcinoma Database Consortium prognostic model in our cohort of patients. Conclusion: We demonstrate that the International Database Consortium prognostic model performs well for European patients treated with TKIs, including sunitinib or sorafenib, after progression on cytokines and suggest that a reduction from original 6 down to 4 parameters is possible.

Cite

POPRACH, A.; Tomáš PAVLÍK; B. MELICHAR; K. KUBACKOVA; Zbyněk BORTLÍČEK; M. SVOBODA; R. LAKOMY; R. VYZULA; I. KISS; Ladislav DUŠEK and T. BUEHLER. Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. New York: ELSEVIER SCIENCE INC., 2014, vol. 32, No 4, p. 488-495. ISSN 1078-1439. Available from: https://dx.doi.org/10.1016/j.urolonc.2013.09.011.

@article{1185400,
   author = {Poprach, A. and Pavlík, Tomáš and Melichar, B. and Kubackova, K. and Bortlíček, Zbyněk and Svoboda, M. and Lakomy, R. and Vyzula, R. and Kiss, I. and Dušek, Ladislav and Buehler, T.},
   article_location = {New York},
   article_number = {4},
   doi = {http://dx.doi.org/10.1016/j.urolonc.2013.09.011},
   keywords = {renal cell carcinoma; prognosis; survival; sunitinib; sorafenib},
   language = {eng},
   issn = {1078-1439},
   journal = {UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS},
   title = {Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines},
   volume = {32},
   year = {2014}
}

TY  - JOUR
ID  - 1185400
AU  - Poprach, A. - Pavlík, Tomáš - Melichar, B. - Kubackova, K. - Bortlíček, Zbyněk - Svoboda, M. - Lakomy, R. - Vyzula, R. - Kiss, I. - Dušek, Ladislav - Buehler, T.
PY  - 2014
TI  - Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines
JF  - UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
VL  - 32
IS  - 4
SP  - 488-495
EP  - 488-495
PB  - ELSEVIER SCIENCE INC.
SN  - 10781439
KW  - renal cell carcinoma
KW  - prognosis
KW  - survival
KW  - sunitinib
KW  - sorafenib
N2  - Objectives: The aim of this retrospective study was to analyze prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors (TKIs) sunitinib or sorafenib after progression on cytokine therapy. Materials and methods: A national database of patients treated with targeted agents was used as the data source. A total of 319 patients treated with sunitinib (n = 181) or sorafenib (n = 138) after progression on cytokine therapy were analyzed. Results: Prognostic factors significantly associated with poor overall survival in a multivariable Cox model included the time from diagnosis to the start of treatment with TKIs <1 year, increased neutrophil counts, increased lactate dehydrogenase, and Eastern Oncology Cooperative Group performance status 2 or higher. The parameters showing statistically significant association with progression-free survival included time from diagnosis to the beginning of treatment with TKI <1 year, increased lactate dehydrogenase, and Eastern Oncology Cooperative Group performance status 2 or higher. We have also validated the International Metastatic Renal Cell Carcinoma Database Consortium prognostic model in our cohort of patients. Conclusion: We demonstrate that the International Database Consortium prognostic model performs well for European patients treated with TKIs, including sunitinib or sorafenib, after progression on cytokines and suggest that a reduction from original 6 down to 4 parameters is possible.
ER  -

POPRACH, A.; Tomáš PAVLÍK; B. MELICHAR; K. KUBACKOVA; Zbyněk BORTLÍČEK; M. SVOBODA; R. LAKOMY; R. VYZULA; I. KISS; Ladislav DUŠEK and T. BUEHLER. Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines. \textit{UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS}. New York: ELSEVIER SCIENCE INC., 2014, vol.~32, No~4, p.~488-495. ISSN~1078-1439. Available from: https://dx.doi.org/10.1016/j.urolonc.2013.09.011.

Přehled o publikaci